Toward the first class of suicide inhibitors of kallikreins involved in skin diseases

J Med Chem. 2015 Jan 22;58(2):598-612. doi: 10.1021/jm500988d. Epub 2014 Dec 22.

Abstract

The inhibition of kallikreins 5 and 7, and possibly kallikrein 14 and matriptase, (that initiates the kallikrein proteolytic cascade) constitutes an innovative way to treat some skin diseases such as Netherton syndrome. We present here the inhibitory properties of coumarin-3-carboxylate derivatives against these enzymes. Our small collection of these versatile organic compounds was enriched by newly synthesized derivatives in order to obtain molecules selective against one, two, three enzymes or acting on the four ones. We evidenced a series of compounds with IC50 values in the nanomolar range. A suicide mechanism was observed against kallikrein 7 whereas the inactivation was either definitive (suicide type) or transient for kallikreins 5 and 14, and matriptase. Most of these potent inhibitors were devoid of cytotoxicity toward healthy human keratinocytes. In situ zymography investigations on skin sections from human kallikrein 5 transgenic mouse revealed significant reduction of the global proteolytic activity by several compounds.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Coumarins / pharmacology*
  • Humans
  • Kallikreins / antagonists & inhibitors*
  • Serine Endopeptidases / physiology
  • Serine Proteinase Inhibitors / pharmacology*
  • Skin Diseases / drug therapy*
  • Skin Diseases / enzymology
  • Structure-Activity Relationship

Substances

  • Coumarins
  • Serine Proteinase Inhibitors
  • KLK5 protein, human
  • KLK7 protein, human
  • Kallikreins
  • Serine Endopeptidases
  • matriptase